These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34653945)

  • 1. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
    Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
    Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
    Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
    Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
    Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
    Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
    Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
    Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
    Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
    Abdizadeh T; Ghodsi R; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.
    Saidahmatov A; Li J; Xu S; Hu X; Gao X; Kan W; Gao L; Li C; Shi Y; Sheng L; Wang P; Zhou Y; Liang X; Li J; Liu H
    J Med Chem; 2024 Sep; 67(17):15220-15245. PubMed ID: 39178382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.